LIMN - Liminatus Pharma, Inc. Class A Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 1.4 -0.16 (-11.43%) | --- | --- | 0.0 (0.0%) | -0.03 (-2.14%) | -0.13 (-9.7%) | -0.09 (-6.77%) | -0.09 (-6.77%) |
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- Diluted EPS:
- Basic P/E:
- Diluted P/E:
- RSI(14) 1m:
- 100.0
- VWAP:
- 1.24
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|---|---|---|
| 1m | Price decrease 1m | 1.21 -0.02 (-1.63%) | Oct 15 16:24 |
| 10m | Price increase 10m | 1.25 +0.04 (+3.31%) | Oct 15 16:22 |
| 10m | Price decrease 10m | 1.2 -0.07 (-5.51%) | Oct 15 16:14 |
| 60m | Price decrease 60m | 1.2 -0.11 (-8.4%) | Oct 15 16:14 |